American Kidney Fund Hosts Fourth National Summit on Unknown Causes of Kidney Disease
December 05, 2023 08:34 ET
|
American Kidney Fund
ROCKVILLE, Md., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) will convene more than 100 medical leaders, patient advocates and academic and industry leaders for the fourth...
American Kidney Fund Renews Calls for Early Diagnosis and Treatment of Chronic Kidney Disease in New Report
November 30, 2023 09:23 ET
|
American Kidney Fund
ROCKVILLE, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Today the American Kidney Fund (AKF) released a new report that urges policymakers and advocates to broadly support measures—including improved...
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
November 29, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...
Africa Healthcare Network (AHN) Secures $20 Million in funding led by Africa50 and AfricInvest for a continent-wide expansion
November 22, 2023 06:30 ET
|
Africa Healthcare Network
Africa Healthcare Network (AHN), a leading provider of dialysis services in Africa, has secured $20 million in equity and debt funding.
ACADEMY OF NUTRITION AND DIETETICS URGES CONGRESS: PASS BILL TO INCREASE ACCESS TO NUTRITION CARE
November 15, 2023 09:00 ET
|
Academy of Nutrition and Dietetics
Chicago, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics supports and advocates for expanded access to medical nutrition therapy and additional coverage for more chronic...
William Moore Joins Healthmap as Chief Information Officer
November 15, 2023 08:00 ET
|
Healthmap Solutions
Healthmap Solutions has named William Moore as Chief Information Officer to oversee expansion of the company’s IT capabilities in kidney care management.
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:15 ET
|
Unicycive Therapeutics, Inc.
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. ...
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023 07:05 ET
|
ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
October 23, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023 07:05 ET
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.